As molecular treatments aimed at dystrophin restoration in DMD are increasingly available as commercialized drugs or within clinical trials, genetic diagnosis has become an indispensable tool in order to determine eligibility for these treatments, which can reduce disease progression and improve the quality of life for affected individuals. This evidence concerns the gene DMD and Duchenne muscular dystrophy.